Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer.
Despite the combined use of surgery and chemoradiotherapy, the poor prognosis of advanced non-small-cell lung cancer (NSCLC) requires the definition of new therapeutic approaches. The presence of T lymphocytes, with peculiar phenotypic, functional and molecular characteristics within the tumour, suggested the possible use of these cells, expanded in vitro, in protocols of adoptive immunotherapy. We have described how a population of oligoclonal T lymphocytes, derived from advanced NSCLC, can be expanded in vitro and has the capability of lysing autologous cancer cells. What is more important, we observed that patients with advanced NSCLC, treated with TIL expanded in vitro and recombinant interleukin-2, seemed to have a disease-free period longer than that of patients treated with conventional chemoradiotherapy. In an attempt to find new sources of specific lymphocytes for immunotherapy, we describe the analysis of the phenotypic, functional and molecular characteristics of T lymphocytes, derived from lymph nodes draining advanced NSCLC. In this paper we show that these cells, have restriction patterns of T cell receptor beta chain similar to those detectable in the population of infiltrating T lymphocytes. This finding suggests that T cells derived from draining lymph nodes of advanced NSCLC have peculiar characteristics and can be a suitable source of effector cells for protocols of adoptive immunotherapy in lung cancer treatment.
Meta
M
M
Servizio di Citometria, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Ponte
M
M
Guastella
M
M
Semino
C
C
Pietra
G
G
Ratto
G B
GB
Melioli
G
G
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology*; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D008198:Lymph Nodes / Q000166:cytology* / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000166:cytology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis; D012680:Sensitivity and Specificity; D013601:T-Lymphocytes / Q000166:cytology* / Q000276:immunology*
D016693:Receptors, Antigen, T-Cell, alpha-beta